Can Zepbound and Mounjaro be used for heart failure?

Yes, Zepbound and Mounjaro’s active ingredient tirzepatide has been used for heart failure in a clinical trial called SUMMIT (NCT04847557). It helped to improve heart failure symptoms and quality of life, reduce the worsening of a heart failure event, and decreased death from cardiovascular causes. The clinical trial used Zepbound and Mounjaro’s active ingredient, tirzepatide, in patients with heart failure with preserved ejection fraction and obesity compared to placebo treatment, over 52 weeks.

The goal of treating heart failure is to slow disease progression (hospitalization and death) and to improve patients' quality of life including their symptoms and ability to move or exercise.

Benefits of Zepbound and Mounjaro for heart failure patients with obesity

• Improved heart failure symptoms and quality of life (tirzepatide +19.5, placebo +12.7) measured using KCCQ-CSS*
• Reduced a worsening of a heart failure event and decreased death from cardiovascular causes.

*The Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) assesses symptoms of heart failure, physical and social limitations, and overall quality of life. Scores range from 0 to 100, where higher scores indicate fewer symptoms and reduced physical limitations.

Tirzepatide (Zepbound and Mounjaro) is currently not FDA-approved for heart failure.

Heart failure with obesity

Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure where the heart maintains a normal or near-normal ejection fraction (LVEF is ≥50%). This type of heart failure is a condition that often occurs in individuals who have higher body weights. Patients with this type of heart failure and obesity have more clinical problems, greater symptoms, and impaired quality of life compared to patients with heart failure with preserved ejection fraction but no obesity.

Reducing body weight in obese HFpEF patients helps to reduce symptoms, as HFpEF patients with lower body weight have fewer symptoms.

Related questions

• Zepbound Vs Mounjaro: Complete Comparison Guide for Weight Loss and Diabetes Treatment
• Ozempic Side Effects to Watch For
• Why am I not losing weight on Mounjaro?

How does Zepbound and Mounjaro improve heart failure?

Zepbound and Mounjaro improve heart failure with preserved ejection fraction (HFpEF) in obese patients by aiding weight loss. Tirzepatide is a GIP and GLP-1 receptor agonist that works by mimicking our natural hormones to:

• Suppress appetite
• Slow gastric emptying
• Increase the feeling of fullness
• Increase insulin release.

Summary

• The active ingredient in Zepbound and Mounjaro (tirzepatide) has been successfully used to treat heart failure with preserved ejection fraction (HFpEF) in obese patients in the clinical trial SUMMIT.
• Tirzepatide helped to improve heart failure symptoms, increase exercise function, and help weight loss.
• Tirzepatide also helped to reduce the worsening of a heart failure event and decrease death from cardiovascular causes.
• Zepbound and Mounjaro (tirzepatide) are currently not FDA-approved to treat heart failure with preserved ejection fraction (HFpEF) in obese patients.